Anika Therapeutics (ANIK) Accumulated Expenses (2016 - 2025)
Historic Accumulated Expenses for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $14.4 million.
- Anika Therapeutics' Accumulated Expenses fell 2317.53% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year decrease of 2317.53%. This contributed to the annual value of $13.6 million for FY2024, which is 354.76% down from last year.
- Latest data reveals that Anika Therapeutics reported Accumulated Expenses of $14.4 million as of Q3 2025, which was down 2317.53% from $11.3 million recorded in Q2 2025.
- In the past 5 years, Anika Therapeutics' Accumulated Expenses registered a high of $19.8 million during Q3 2023, and its lowest value of $11.3 million during Q2 2025.
- In the last 5 years, Anika Therapeutics' Accumulated Expenses had a median value of $16.4 million in 2021 and averaged $16.2 million.
- As far as peak fluctuations go, Anika Therapeutics' Accumulated Expenses skyrocketed by 2961.99% in 2023, and later crashed by 3153.27% in 2025.
- Quarter analysis of 5 years shows Anika Therapeutics' Accumulated Expenses stood at $17.8 million in 2021, then rose by 5.56% to $18.8 million in 2022, then fell by 25.34% to $14.1 million in 2023, then decreased by 3.55% to $13.6 million in 2024, then rose by 5.82% to $14.4 million in 2025.
- Its Accumulated Expenses stands at $14.4 million for Q3 2025, versus $11.3 million for Q2 2025 and $12.6 million for Q1 2025.